GuidelineDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2016
Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
Guideline in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05460403 (Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection), which is not on this map. Cited by 122 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection
Who cites it
122 citing papers in PubMed, 4 syntheses or guidelines pooled it, 276 citations in OpenAlex.
- Current Evidence and Future Perspective of Accuracy of Artificial Intelligence Application for Early Gastric Cancer Diagnosis With Endoscopy: A Systematic and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.Updates in surgery · 2019Guideline
- Clinical Value of Long Noncoding RNA HOTAIR as a Novel Biomarker in Digestive Cancers: A Meta-Analysis.Technology in cancer research & treatment · 2018Pooled it
- Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2016Guideline
- Article
- Prognostic nutritional index is associated with severe postoperative complications after neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma: a retrospective cohort study with threshold effect analysis.Journal of cardiothoracic surgery · 2026Article
- Clinical outcomes of esophageal squamous cell carcinoma with pathological complete response after neoadjuvant chemoradiotherapy and surgery.Surgical endoscopy · 2026Article
- Development and validation of a CT radiomics nomogram for preoperative prediction of right recurrent laryngeal nerve lymph node metastasis in thoracic esophageal squamous cell carcinoma.Journal of thoracic disease · 2026Article
- Prophylactic Supraclavicular Lymphadenectomy Does Not Improve Prognosis in Upper and Middle Thoracic Esophageal Squamous Cell Carcinoma: A Retrospective Single-Center Study.Medicina (Kaunas, Lithuania) · 2026Article
- Survival Outcomes of Adjuvant Nivolumab after Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026Article
- Residual disease subtyping predicts survival and guides adjuvant immunotherapy in esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.Frontiers in immunology · 2026Article
- The predictive value of prognostic immune and nutritional index in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy: a retrospective propensity score matching study.Frontiers in immunology · 2026Article
- Article
- Retrospective comparative study of video- and robot-assisted esophagectomy after neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.Surgical endoscopy · 2025Article
- Low levels of tumor suppressor miR-3619 in plasma contribute to malignant outcomes and a target for nucleic acid therapy in esophageal cancer.Scientific reports · 2025Article
- Real-world applications of postneoadjuvant stage I of the staging system for oesophageal squamous cell cancer: what is beyond a pathological complete response?European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025Article
- Calmodulin-Like Protein 5 (CALML5) Expression in Squamous Cell Carcinoma of Esophagus and Oropharynx.Acta histochemica et cytochemica · 2025Article
- Subclassification scheme for adenocarcinomas of the esophagogastric junction and prognostic analysis based on clinicopathological features.World journal of gastrointestinal oncology · 2025Article
- Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Serum creatinine to cystatin C ratio is a prognostic indicator in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.Frontiers in immunology · 2025Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
We report analytic and consensus processes that produced recommendations for pathologic stage groups (pTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration provided data for 22,654 patients with epithelial esophageal cancers; 13,300 without preoperative therapy had pathologic assessment after esophagectomy or endoscopic treatment. Risk-adjusted survival for each patient was developed using random survival forest analysis to identify data-driven pathologic stage groups wherein survival decreased monotonically with increasing group, was distinctive between groups, and homogeneous within groups. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced consensus pathologic stage groups. For pT1-3N0M0 squamous cell carcinoma (SCC) and pT1-2N0M0 adenocarcinoma, pT was inadequate for grouping; subcategorizing pT1 and adding histologic grade enhanced staging; cancer location improved SCC staging. Consensus eliminated location for pT2N0M0 and pT3N0M0G1 SCC groups, and despite similar survival, restricted stage 0 to pTis, excluding pT1aN0M0G1. Metastases markedly reduced survival; pT, pN, and pM sufficiently grouped advanced cancers. Stage IIA and IIB had different compositions for SCC and adenocarcinoma, but similar survival. Consensus stage IV subgrouping acknowledged pT4N+ and pN3 cancers had poor survival, similar to pM1. Anatomic pathologic stage grouping, based on pTNM only, produced identical consensus stage groups for SCC and adenocarcinoma at the cost of homogeneity in early groups. Pathologic staging can neither direct pre-treatment decisions nor aid in prognostication for treatment other than esophagectomy or endoscopic therapy. However, it provides a clean, single therapy reference point for esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.